GUANZE MEDICAL Issues Profit Warning, Anticipates Net Loss Attributable to Shareholders of RMB 28-30 Million for FY 2025

Stock News
Mar 18

GUANZE MEDICAL (02427) has announced an expected net loss attributable to company owners in the range of RMB 28 million to RMB 30 million for the twelve-month period ending December 31, 2025. This contrasts with a net profit of approximately RMB 17.2 million reported for the same period ending December 31, 2024. The anticipated loss for the current period is primarily attributed to a combination of factors: a decrease in both the average selling price and sales volume of imaging film products in 2025 compared to 2024; a decline in sales revenue from approximately RMB 155.7 million in 2024 to about RMB 88.4 million in 2025; and a potential impairment of property, plant, and equipment in 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10